Informations générales (source: ClinicalTrials.gov)
Study of the Prevalence of Deep Vein Thrombosis in Patients Hospitalized in Intensive Care for Acute Respiratory Failure Linked to Pneumonia Documented With SARS-COV2 (CLOT)
Observational
Ramsay Générale de Santé (Voir sur ClinicalTrials)
mai 2020
septembre 2020
29 juin 2024
Coronavirus 2 (SARS-CoV2) has been identified as the pathogen responsible for severe
acute respiratory syndrome associated with severe inflammatory syndrome and pneumonia
(COVID-19).
Haemostasis abnormalities have been shown to be associated with a poor prognosis in these
patients with this pneumonia. In a Chinese series of 183 patients, the hemostasis balance
including thrombin time, fibrinogenemia, fibrin degradation products and antithrombin III
were within normal limits. Only the D-Dimer assay was positive in the whole cohort with
an average rate of 0.66 µg / mL (normal <50 µg / mL). These hemostasis parameters were
abnormal mainly in patients who died during their management; the levels of D-dimers and
fibrin degradation products were significantly higher while the antithrombin III was
reduced. The findings on the particular elevation of D-dimers in deceased patients as
well as the significant increase in thrombin time were also reported in another series.
Higher numbers of pulmonary embolisms have been reported in patients with severe form of
SARS-COV2 (data in press).
This research is based on the hypothesis that the existence of deep vein thrombosis (DVT)
could make it possible to screen patients at risk of pulmonary embolism and to set up a
curative anticoagulation.
The main objective is to describe the prevalence of deep vein thrombosis in patients
hospitalized in intensive care for acute respiratory failure linked to documented
SARS-COV2 pneumonia, within 24 hours of their admission.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CENTRE CARDIOLOGIQUE DU NORD | Julien Nahum, Dr | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hôpital Ambroise Paré - 92100 - Boulogne-Billancourt - IDF - France | Guillaume Peri, Dr | Contact (sur clinicalTrials) | |||
| Hôpital Privé Jacques Cartier - 91300 - Massy - IDF - France | DRE Ramsay santé | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient, male or female, over 18 years of age with no upper age limit.
- Patient admitted to intensive care or intensive care for pneumonia linked to
SARS-COV2 (diagnosed on positive PCR or chest CT and anamnesis)
- Affiliated patient or beneficiary of a social security scheme
- Patient having been informed and not objecting to the use of their data in the
context of this research.
- Patient, male or female, over 18 years of age with no upper age limit.
- Patient admitted to intensive care or intensive care for pneumonia linked to
SARS-COV2 (diagnosed on positive PCR or chest CT and anamnesis)
- Affiliated patient or beneficiary of a social security scheme
- Patient having been informed and not objecting to the use of their data in the
context of this research.
- Pregnant, lactating or parturient woman
- Protected patient: adult under guardianship, curatorship or other legal protection,
deprived of liberty by judicial or administrative decision.